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citrated plasma-evoked oxidative and inflammatory
reactions in endothelial cells by up-regulating
protease-activated receptor-1 expression
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Advanced glycation end products (AGEs) and receptor RAGE interaction contribute to endothelial cell damage in
diabetes. Several thrombogenic abnormalities are also involved in diabetic vascular complications. However, the
pathological role of thrombin and protease-activated receptor-1 (PAR-1) system in AGE-induced endothelial cell (EC)
damage remains unclear. In this study, we investigated the effects of rivaroxaban, an inhibitor of factor Xa on 3%
citrated human plasma-evoked reactive oxygen species (ROS) generation and RAGE, monocyte chemoattractant
protein-1 (MCP-1) and intercellular adhesion molecule-1 (ICAM-1) gene expression in AGE-exposed ECs. We further
examined whether FR171113, an inhibitor of PAR-1 blocked the plasma-induced EC damage and if AGEs increased
PAR-1 expression in ECs. Human citrated plasma stimulated ROS generation and RAGE, MCP-1 and ICAM-1 expression
in ECs, all of which were potentiated by the treatment with AGEs. Rivaroxaban or FR171113 significantly inhibited these
derangements in plasma- or plasma plus AGE-exposed ECs. Moreover, AGEs significantly increased the PAR-1 levels in
ECs. The present study suggests that citrated plasma could induce oxidative and inflammatory reactions in ECs via the
activation of thrombin-PAR-1 system and that AGEs could potentiate the plasma-evoked EC damages via up-regulation
of PAR-1. Blockade of the crosstalk between AGE-RAGE axis and coagulation system by rivaroxaban might be a novel
therapeutic target for thromboembolic disorders in diabetes.
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Sugars, including glucose, fructose and trioses can react
non-enzymatically with the amino groups of proteins,
lipids and nucleic acids to form reversible Schiff bases,
and then Amadori products [1-3]. These early glycation
products undergo further complex reactions such as re-
arrangement, dehydration and condensation to become
irreversibly cross-linked, heterogeneous fluorescent
derivatives called “advanced glycation end products
(AGEs)” [1-3]. The formation and accumulation of AGEs
in various tissues have been known to progress at a
physiological aging and at an accelerated rate under* Correspondence: shoichi@med.kurume-u.ac.jp
1Department of Pathophysiology and Therapeutics of Diabetic Vascular
Complications, Kurume University School of Medicine, 67 Asahi-machi,
Kurume 830-0011, Japan
Full list of author information is available at the end of the article
© 2014 Ishibashi et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.hyperglycemic conditions [1-3]. There is an accumulat-
ing body of evidence that engagement of receptor for
AGEs (RAGE) with the ligand AGEs elicits oxidative
stress generation and resultantly evokes inflammatory
and thrombogenic reactions in endothelial cells (ECs),
thereby playing a central role in vascular complications
in diabetes [4-9].
Several types of thrombogenic abnormalities have also
contributed to the development and progression of vas-
cular damage and thromboembolic disorders in patients
with diabetes [10-13]. AGEs not only inhibit prostacyclin
production in ECs through the interaction with RAGE,
but also induce plasminogen activator inhibitor-1, thus
promoting platelet aggregation and fibrin stabilization,
thus resulting in a predisposition to thrombogenesis in
diabetes [10,14]. Furthermore, the AGE-RAGE inter-
action stimulates tissue factor expression in ECs, beingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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However, the pathological role of thrombin and protease-
activated receptor-1 (PAR-1) system in AGE-induced EC
damage remains unclear. Therefore, in this study, we in-
vestigated the effects of rivaroxaban, an inhibitor of factor
Xa on 3% citrated human plasma-evoked reactive oxygen
species (ROS) generation and RAGE, monocyte chemo-
attractant protein-1 (MCP-1) and intercellular adhesion
molecule-1 (ICAM-1) gene expression in AGE-exposed
human umbilical vein ECs (HUVECs). We further exam-
ined whether FR171113, an inhibitor of PAR-1 blocked
the plasma-induced EC damage and if AGEs increased the
PAR-1 expression in HUVECs.
Methods
Materials
An inhibitor of Xa, rivaroxaban was purchased from
Tronto Research Chemicals Inc. (Toronto, Canada). CitFigure 1 Effects of ribaroxaban (A) and DPI (B) on superoxide generatio
concentrations of ribaroxaban for 30 min and treated with 100 μg/ml AGE-BS
presence or absence of 50 nM DPI for 4 hr. Then the cells were incubated wit
Each lower panel shows quantitative data of ROS generation evaluated by flu
compared to the value with BSA + 3% human plasma alone, respectively. ##,rated human plasma from Tennessee Blood Sciences,
Memphis, TN, USA. Bovine serum albumin (BSA) (essen-
tially fatty acid free and essentially globulin free, lyophilized
powder), diphenylene iodonium (DPI) and a blocker of
PAR-1, FR171113 were from Sigma (St. Louis, MO, USA).
D-glyceraldehyde was purchased from Nakalai Tesque
(Kyoto, Japan).Preparation of AGE-BSA
AGE-BSA was prepared as described previously [16]. In
brief, BSA (25 mg/ml) was incubated under sterile condi-
tions with 0.1 M glyceraldehyde in 0.2 M NaPO4 buffer
(pH 7.4) for 7 days. Then unincorporated sugars were re-
moved by PD-10 column chromatography and dialysis
against phosphate-buffered saline. Control non-glycated
BSA was incubated in the same conditions except for the
absence of reducing sugars. Preparations were tested forn in HUVECs. HUVECs were pre-incubated with or without the indicated
A, 100 μg/ml non-glycated BSA or 3% citrated human plasma in the
h DHE. Each upper panel shows typical microphotographs of the cells.
orescent intensity. N = 5-10 per group. * and **, p < 0.05 and p < 0.01
p < 0.01 compared to the value with AGEs + 3% human plasma alone.
Figure 2 Effects of ribaroxaban on RAGE gene expression in HUVECs. HUVECs were pre-incubated with or without the indicated concentrations
of ribaroxaban for 30 min and treated with 100 μg/ml AGE-BSA, 100 μg/ml non-glycated BSA or 3% citrated human plasma for 4 hr. Then total RNAs
were transcribed and amplified by real-time PCR. Data were normalized by the intensity of β-actin mRNA-derived signals and then related to the value
obtained with BSA alone. N = 3 per group. * and **, p < 0.05 and p < 0.01 compared to the value with BSA + 3% human plasma alone, respectively.
##, p < 0.01 compared to the value with AGEs + 3% human plasma alone.
Figure 3 Effects of ribaroxaban on MCP-1 (A) and ICAM-1 (B) gene expression in HUVECs. HUVECs were pre-incubated with or without the
indicated concentrations of ribaroxaban for 30 min and treated with 100 μg/ml AGE-BSA, 100 μg/ml non-glycated BSA or 3% citrated human
plasma for 4 hr. Then total RNAs were transcribed and amplified by real-time PCR. Data were normalized by the intensity of 18S mRNA-derived
signals and then related to the value obtained with BSA alone. N = 5 per group. * **, p < 0.01 compared to the value with BSA + 3% human
plasma alone. #, p < 0.05 compared to the value with AGEs + 3% human plasma alone.
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Co., Tokyo, Japan); no endotoxin was detectable.
Cells
HUVECs obtained from Lonza Group Ltd. (Basel,
Switzerland) were cultured in endothelial basal medium
supplemented with 2% fetal bovine serum, 0.4% bovine
brain extracts, 10 ng/ml human epidermal growth factor
and 1 μg/ml hydrocortisone according to the supplier’s
instructions. Rivaroxaban or AGE treatment was carried
out in a medium lacking fetal bovine serum, epidermal
growth factor and hydrocortisone.
Dihydroethidium (DHE) staining
HUVECs were pre-incubated with or without the indi-
cated concentrations of rivaroxaban for 30 min and
treated with 100 μg/ml AGE-BSA, 100 μg/ml non-
glycated BSA or 3% citrated human plasma in theFigure 4 Effects of FR171113 or rivaroxaban on superoxide generatio
THP-1 cell adhesion to (E), HUVECs. HUVECs were pre-incubated with or
absence of 3% citrated human plasma or 1 mM FR171113 for 4 hr. (A) The
by fluorescent intensity. N = 5 per group. (B-D) Total RNAs were transcribed
sity of β-actin (B) or 18S mRNA-derived signals ((C) and (D)) and then rela
adhesion to HUVECs was evaluated. (B) N = 7 per group. (C) and (D) N = 3
pared to the value with BSA + 3% human plasma alone, respectively.presence or absence of 50 nM DPI, 1 mM FR171113 for
4 hr. Then the cells were incubated with phenol red free
Dulbecco's Modified Eagle Medium containing 3 μM
DHE (Molecular Probes Inc., Eugene, OR, USA). After
15 minutes, the cells were imaged under a laser-scanning
confocal microscope. Superoxide generation was evaluated
by intensity of DHE staining. The intensity was analyzed
by microcomputer-assisted NIH image.
Real-time reverse transcription-polymerase chain
reactions (RT-PCR)
HUVECs were pre-incubated with or without the indicated
concentrations of rivaroxaban for 30 min and treated with
100 μg/ml AGE-BSA, 100 μg/ml non-glycated BSA or 3%
citrated human plasma in the presence or absence of 1 mM
FR171113 for 4 hr. Then total RNA was extracted with
RNAqueous-4PCR kit (Ambion Inc., Austin, TX, USA) ac-
cording to the manufacturer’s instructions. Quantitativen (A), RAGE (B), MCP-1 (C), ICAM-1 (D) gene expression in, and
without 30 nM ribaroxaban for 30 min and treated in the presence or
n the cells were incubated with DHE. ROS generation was evaluated
and amplified by real-time PCR. Data were normalized by the inten-
ted to the value obtained with non-glycated BSA alone. (E) THP-1 cell
per group. (E) N = 6 per group. * and **, p < 0.05 and p < 0.01 com-
Figure 5 Western blot analysis for PAR-1. HUVECs were treated
with or without 100 μg/ml AGE-BSA or 100 μg/ml non-glycated
BSA for 4 hr. Then proteins were extracted from HUVECs with lysis
buffer, separated by SDS-PAGE and transferred to nitrocellulose
membranes. Membranes were probed with antibodies raised against
PAR-1 or α-tubulin, and then immune complexes were visualized
with an enhanced chemiluminescence detection system. Upper
panel shows the representative bands of western blots. Lower panel
shows the quantitative data. Data were normalized by the intensity of
α-tubulin-derived signals and related to the value with non-glycated
BSA. N = 3 per group.
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and TaqMan 5 fluorogenic nuclease chemistry (Applied
Biosystems, Foster city, CA, USA) according to the sup-
plier’s recommendation. IDs of primers for human RAGE,
MCP-1, ICAM-1, β-actin and 18S gene were Hs00
153957_m1, Hs00234140_m1, Hs00164932_m1, Hs99999
903_m1, and Hs99999901_s1, respectively.
Assay of THP-1 cell adhesion to HUVECs
Human THP-1 monocytic leukemia cells (American Type
Culture Collection, Manassas, VA, USA) were maintained
in RPMI 1640 medium supplemented with 1% GultaMAX
(Life Technologies Corporation, Carlsbad, CA, USA) and
1% fetal bovine serum (NICHIREI BIOSCIENCES INC,
Tokyo, Japan). THP-1 cells were labeled with 3 mM
BCECF-AM (Dojindo, Kumamoto, Japan) at 37°C for
30 min according to the supplier’s recommendation.
THP-1 cell adhesion to HUVECs was assayed according
to the method described previously [17]. Briefly, HUVECs
were treated with or without 100 μg/ml non-glycated BSA
or 3% citrated human plasma in the presence or absence
of 30 nM rivaroxaban for 4 hr, and then incubated with
BCECF-AM-labeled THP-1 cells for 4 hr. After the incu-
bation, nonadherent THP-1 cells were removed by wash-
ing the HUVECs gently. Fluorescent intensities of the
adherent THP-1 cells were measured.
Western blot analysis
HUVECs were treated with or without 100 μg/ml AGE-
BSA or 100 μg/ml non-glycated BSA for 4 hr. Then proteins
were extracted from HUVECs with lysis buffer, separated by
SDS-PAGE and transferred to nitrocellulose membranes as
described previously [18]. Membranes were probed with
antibodies raised against PAR-1 (Santa Cruz Biotech-
nology Inc., Delaware, CA, USA) or α-tubulin (Santa
Cruz Biotechnology Inc.), and then immune complexes
were visualized with an enhanced chemiluminescence
detection system (Amersham Bioscience, Buckinghamshire,
United Kingdom).
Statistical analysis
All values were presented as means ± standard error.
Student’s t-test or one-way analysis of variance followed
Tukey’s test was performed for statistical comparisons;
p < 0.05 was considered significant. All statistical analyses
were performed with the use of the PASW Statistics system
(version 18.0; IBM Corporation, New York, NY, USA).
Results
We first examined the effects of rivaroxaban on citrated
plasma-evoked superoxide generation in HUVECs. As
shown in Figure 1A, rivaroxaban dose-dependently de-
creased the plasma-elicited ROS generation in HUVECs.
Rivaroxaban itself did not affect the ROS generation inHUVECs. Furthermore, AGEs potentiated the plasma-
induced ROS generation in HUVECs, which was also
significantly inhibited by the treatment with rivaroxaban.
An inhibitor of NADPH oxidase, DPI was found to inhibit
the 3% citrated human plasma-induced ROS generation in
HUVECs (Figure 1B).
We next studied whether plasma could up-regulate
RAGE gene expression in HUVECs. As shown in Figure 2,
plasma increased RAGE mRNA levels in HUVECs, which
was suppressed by rivaroxaban. Moreover, AGEs further
increased RAGE mRNA levels in plasma-exposed HUVEC,
which was also blocked by rivaroxaban.
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nificantly inhibited the plasma-induced up-regulation of
MCP-1 and ICAM-1 mRNA levels in HUVECs (Figure 3).
These mRNA levels were further increased by the treat-
ment with AGEs, both of which were significantly sup-
pressed by rivaroxaban.
We investigated how plasma induced the ROS gener-
ation and subsequently evoked the inflammatory reactions
in HUVECs. As shown in Figure 4A, a blocker of PAR-1,
FR171113 completely inhibited the plasma-induced ROS
generation in HUVECs. Moreover, FR171113 significantly
prevented the plasma-elicited up-regulation of RAGE,
MCP-1 and ICAM-1 mRNA levels in HUVECs (Figure 4B-
D). We further studied whether rivaroxaban could inhibit
the plasma-evoked THP-1 cell adhesion to HUVECs. As
shown in Figure 4E, 3% citrated human plasma increased
THP-1 cell adhesion to HUVECs by about 1.4-fold. Thirty
nM rivaroxaban significantly inhibited the THP-1 cell adhe-
sion to plasma-exposed HUVECs.
In addition, AGEs significantly increased the PAR-1
protein levels in HUVECs; PAR-1 levels were increased
to 1.3-fold of that of non-glycated BSA-treated HUVECs
(Figure 5).
Discussion
Citrated plasma-evoked EC injury
We chose the condition of 100 μg/ml AGE-BSA for
4 hr in the present experiments because we have previ-
ously found that ROS generation and inflammatory re-
actions of ECs reach a maximum at 4 h in the presence
of 100 μg/ml AGE-BSA [16,19]. In this study, we found
for the first time that 3% citrated plasma increased
ROS generation, up-regulated RAGE, MCP-1 and ICAM-
1 mRNA levels in, and stimulated THP-1 cell adhesion to,Figure 6 Possible participation of the AGE-RAGE axis in thrombin-evoHUVECs, all of which were significantly blocked by the
treatment with rivaroxaban, an inhibitor of Xa (Figures 1, 2,
3 and 4). Furthermore, 3% citrated human plasma-evoked
ROS generation, RAGE, MCP-1 and ICAM-1 gene induc-
tion was significantly blocked by the treatment with a
blocker of PAR-1, FR171113 (Figure 4). Since calcium level
in HUVEC basal medium used here (6.4 mg/dl) is almost
equal to that of human serum, citrated plasma is re-
calcified and thrombin could be generated in the cell cul-
ture medium. Therefore, rivaroxaban could inhibit the for-
mation of thrombin from prothrombin via blockade of Xa,
thereby suppressing the thrombin-PAR-1-induced ROS
generation in HUVECs (Figure 6). In the present study, we
also found that an inhibitor of NADPH oxidase, DPI sup-
pressed the plasma-induced ROS generation in HUVECs.
So, re-calcified citrated plasma might evoke the ROS gen-
eration in HUVECs through he activation of NADPH oxi-
dase via the interaction of thrombin with PAR-1. NADPH
oxidase was shown to be necessary for thrombin-induced
signaling pathway in vascular cells, thus supporting our
speculation [20].
There is accumulating evidence that thrombin could
elict the EC activation via PAR-1 [21-23]. Indeed,
thrombin-PAR-1 interaction has induced MCP-1 and
ICAM-1 expression in HUVECs [21-23]. We have previ-
ously shown that gene expression of MCP-1 and ICAM-
1 in ECs is induced by ROS generation via the activation
of nuclear factor-κB (NF-κB) [24-29]. Moreover, throm-
bin has been shown to induce the MCP-1 and ICAM-1
gene expression in HUVECs via NF-κB [30-33]. So, the
present findings suggest that recalcified plasma may
stimulate MCP-1 and ICAM-1 mRNA levels in HUVECs
through transcriptional activation of redox-sensitive
transcriptional factor NF-κB.ked EC injury.
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Risks for various thromboembolic disorders are high in
diabetes [10-13]. In the present study, we found that AGEs
potentiated the 3% citrated human plasma-evoked ROS
generation, RAGE, MCP-1 and ICAM-1 gene expression
in HUVECs (Figures 1, 2 and 3). Further, PAR-1 expres-
sion was significantly induced by the treatment with AGEs
(Figure 5). These observations suggest that AGEs could
enhance the plasma-evoked thrombin signaling pathways
in HUVECs via enhancement of PAR-1 expression. So,
rivaroxaban might block the deleterious effects of AGEs
on HUVECs by reducing the thrombin formation and
subsequently suppressing the thrombin-PAR-1 axis. In
this study, recalcified plasma induced ROS generation and
RAGE gene induction, which could further potentiate the
AGE-signaling pathways in HUVECs again. Since rivarox-
aban inhibited the plasma-elicited ROS generation and
RAGE gene expression in HUVECs, our present study
suggests that blockade of the pathological crosstalk be-
tween the AGE-RAGE axis and thrombin-PAR-1 system
by rivaroxaban might be a novel therapeutic strategy for
reducing the risk of thromboembolic disorders in patients
with diabetes [34].
AGE-RAGE axis has been reported to mediate atrial
structural remodeling in the diabetic rats, thus increas-
ing the risk of atrial fibrillation (AF) in diabetes [35].
Furthermore, recently, both plasma levels of AGEs and
soluble RAGE, a marker of RAGE activation were shown
to be higher in patients with AF, positively correlated
with atrial dimensions, thus indicating a pathological
role for the AGE-RAGE axis in the arrhythmogenic
atrial structural remodeling in humans [36]. These find-
ings further support the clinical relevance of suppression
of the AGE-RAGE axis for the prevention of AF. The
peak plasma concentration of rivaroxaban after adminis-
tration of single oral dose of 10 mg is reported to be
about 300-400 nM [37]. So, the concentration of rivar-
oxaban having beneficial effects on HUVECs used in the
present experiments (30-300 nM) may also be compar-
able to the therapeutic level which is achieved in the
treatment for patients with AF.
Limitations
In this study, in vitro-modified AGEs were prepared by in-
cubating BSA with glyceraldehyde for 1 week; this process
produced relatively highly-modified proteins in comparison
to those in vivo. However, it was unlikely that extensively-
modified, unphysiologic AGEs that were formed under the
in vitro-conditions may exert non-specific effects on
HUVECs because we have previously found that immuno-
logical epitope of glyceraldehyde-modified AGEs is actually
present in serum of diabetic patients and that the concen-
tration (100 μg/ml) of in vitro-prepared AGEs used here are
comparable with those of the in vivo diabetic situation [38].An in vivo-animal model is needed to evaluate the
in vitro-findings of rivaroxaban observed here. Inhibition
of RAGE may help to demonstrate the relation between
the AGE-RAGE axis and thrombin-PAR-1 system. In
addition, further clinical intervention trials are also needed
to clarify whether blockade of the crosstalk between the
AGE-RAGE axis and thrombin-PAR-1 axis could actually
decrease the risk of thromboembolic disorders and slow
the progression of atherosclerosis in patients with AF, es-
pecially in diabetic subjects. Lastly, we have to mention
about the adverse effects of rivaroxaban, i.e., more bleed-
ing, if it is widely used especially for high-risk patients.
Conclusions
Our present observations suggest citrated plasma could in-
duce oxidative and inflammatory reactions in ECs via the ac-
tivation of thrombin-PAR-1 system, which was potentiated
by AGEs. Blockade of the crosstalk between AGE-RAGE axis
and coagulation system might be a novel therapeutic target
for thromboembolic disorders in diabetes (Figure 6).
Abbreviations
AGEs: Advanced glycation end products; RAGE: Receptor for AGEs;
ECs: Endothelial cells; PAR-1: Protease-activated receptor-1; ROS: Reactive
oxygen species; MCP-1: Monocyte chemoattractant protein-1; ICAM-1: Intercellular
adhesion molecule-1; HUVECs: Human umbilical vein ECs; BSA: Bovine serum
albumin; DPI: Diphenylene iodonium; DHE: Dihydroethidium; RT-PCR: Reverse
transcription-polymerase chain reaction; NF-κB: Nuclear factor-κB;
AF: Atrial fibrillation.
Competing interests
This project was financially supported by Bayer AG. Dr. Yamagishi, Dr. Ueda
and Dr. Fukami have received honoraria such as lecture fees from Bayer AG.
Authors’ contributions
YI, TM, SU and KF acquired and interpreted data. SY mainly contributed to
the present study, conceptualized and designed the study, acquired,
analyzed, and interpreted data, and drafted the manuscript, and took
responsibility for the integrity of the data and the accuracy of the data
analysis. All authors read and approved the final manuscript.
Acknowledgments
This study was supported in part by Grants-in-Aid for Scientific Research
(B) from the Ministry of Education, Culture, Sports, Science and Technology,
Japan (to S.Y.), and by MEXT-Supported Program for the Strategic Research
Foundation at Private Universities, the Ministry of Education, Culture, Sports,
Science and Technology (MEXT) (to S.Y.).
Author details
1Department of Pathophysiology and Therapeutics of Diabetic Vascular
Complications, Kurume University School of Medicine, 67 Asahi-machi,
Kurume 830-0011, Japan. 2Department of Medicine, Kurume University
School of Medicine, Kurume 830-0011, Japan.
Received: 12 December 2013 Accepted: 8 March 2014
Published: 13 March 2014
References
1. Vlassara H, Bucala R: Recent progress in advanced glycation and diabetic
vascular disease: role of advanced glycation end product receptors.
Diabetes 1996, 45(Suppl 3):S65–66.
2. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products
in tissue and the biochemical basis of diabetic complications. N Engl J
Med 1988, 318:1315–1321.
Ishibashi et al. Cardiovascular Diabetology 2014, 13:60 Page 8 of 8
http://www.cardiab.com/content/13/1/603. Rahbar S: Novel inhibitors of glycation and AGE formation. Cell Biochem
Biophys 2007, 48:147–157.
4. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T,
Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H:
Development and prevention of advanced diabetic nephropathy in
RAGE-overexpressing mice. J Clin Invest 2001, 108:261–268.
5. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL,
Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth
PP, Stern DM, D'Agati VD, Schmidt AM: RAGE drives the development of
glomerulosclerosis and implicates podocyte activation in the
pathogenesis of diabetic nephropathy. Am J Pathol 2003, 162:1123–1137.
6. Yamagishi S, Imaizumi T: Diabetic vascular complications:
pathophysiology, biochemical basis and potential therapeutic strategy.
Curr Pharm Des 2005, 11:2279–2299.
7. Yamagishi S, Nakamura K, Matsui T, Noda Y, Imaizumi T: Receptor for
advanced glycation end products (RAGE): a novel therapeutic target for
diabetic vascular complication. Curr Pharm Des 2008, 14:487–495.
8. Jandeleit-Dahm K, Cooper ME: The role of AGEs in cardiovascular disease.
Curr Pharm Des 2008, 14:979–986.
9. Tahara N, Yamagishi S, Takeuchi M, Honda A, Tahara A, Nitta Y, Kodama N,
Mizoguchi M, Kaida H, Ishibashi M, Hayabuchi N, Matsui T, Imaizumi T:
Positive association between serum level of glyceraldehyde-derived
advanced glycation end products and vascular inflammation evaluated
by [(18)F]fluorodeoxyglucose positron emission tomography. Diabetes
Care 2012, 35:2618–2625.
10. Takenaka K, Yamagishi S, Matsui T, Nakamura K, Imaizumi T: Role of
advanced glycation end products (AGEs) in thrombogenic abnormalities
in diabetes. Curr Neurovasc Res 2006, 3:73–77.
11. Alzahrani SH, Ajjan RA: Coagulation and fibrinolysis in diabetes. Diab Vasc
Dis Res 2010, 7:260–273.
12. Piazza G, Goldhaber SZ, Kroll A, Goldberg RJ, Emery C, Spencer FA: Venous
thromboembolism in patients with diabetes mellitus. Am J Med 2012, 125:709–716.
13. Klem I, Wehinger C, Schneider B, Hartl E, Finsterer J, Stöllberger C: Diabetic
atrial fibrillation patients: mortality and risk for stroke or embolism
during a 10-year follow-up. Diabetes Metab Res Rev 2003, 19:320–328.
14. Yamagishi S, Fujimori H, Yonekura H, Yamamoto Y, Yamamoto H: Advanced
glycation endproducts inhibit prostacyclin production and induce
plasminogen activator inhibitor-1 in human microvascular endothelial
cells. Diabetologia 1998, 41:1435–1441.
15. Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, Wahl
P, Ziegler R, Müller M, Nawroth PP: Advanced glycation end product
(AGE)-mediated induction of tissue factor in cultured endothelial cells is
dependent on RAGE. Circulation 1997, 96:2262–2271.
16. Yamagishi S, Nakamura K, Matsui T, Inagaki Y, Takenaka K, Jinnouchi Y, Yoshida Y,
Matsuura T, Narama I, Motomiya Y, Takeuchi M, Inoue H, Yoshimura A, Bucala R,
Imaizumi T: Pigment epithelium-derived factor inhibits advanced glycation
end product-induced retinal vascular hyperpermeability by blocking reactive
oxygen species-mediated vascular endothelial growth factor expression. J Biol
Chem 2006, 281:20213–20220.
17. Yamagishi S, Kikuchi S, Nakamura K, Matsui T, Makino T, Norisugi O, Shimizu T,
Inoue H, Imaizumi T: Pigment epithelium-derived factor (PEDF) blocks
angiotensin II-induced T cell adhesion to endothelial cells by suppressing
intercellular adhesion molecule-1. Horm Metab Res 2006, 38:546–548.
18. Ojima A, Ishibashi Y, Matsui T, Maeda S, Nishino Y, Takeuchi M, Fukami K,
Yamagishi S: Glucagon-like peptide-1 receptor agonist inhibits asymmetric
dimethylarginine generation in the kidney of streptozotocin-induced
diabetic rats by blocking advanced glycation end product-induced protein
arginine methyltranferase-1 expression. Am J Pathol 2013, 182:132–141.
19. Si Y, Yonekura H, Yamamoto Y, Katsuno K, Sato F, Mita I, Ooka H, Satozawa
N, Kawakami T, Nomura M, Yamamoto H: Advanced glycation end
products-driven angiogenesis in vitro. Induction of the growth and tube
formation of human microvascular endothelial cells through autocrine
vascular endothelial growth factor. J Biol Chem 1997, 272:8723–8730.
20. Du J, Brink M, Peng T, Mottironi B, Delafontaine P: Thrombin regulates insulin-
like growth factor-1 receptor transcription in vascular smooth muscle:
characterization of the signaling pathway. Circ Res 2001, 88:1044–1052.
21. Wei HJ, Li YH, Shi GY, Liu SL, Chang PC, Kuo CH, Wu HL: Thrombomodulin
domains attenuate atherosclerosis by inhibiting thrombin-induced
endothelial cell activation. Cardiovasc Res 2011, 92:317–327.
22. Delekta PC, Apel IJ, Gu S, Siu K, Hattori Y, McAllister-Lucas LM, Lucas PC:
Thrombin-dependent NF-{kappa}B activation and monocyte/endothelialadhesion are mediated by the CARMA3 · Bcl10 · MALT1 signalosome.
J Biol Chem 2010, 285:41432–41442.
23. Lin Z, Hamik A, Jain R, Kumar A, Jain MK: Kruppel-like factor 2 inhibits
protease activated receptor-1 expression and thrombin-mediated
endothelial activation. Arterioscler Thromb Vasc Biol 2006, 26:1185–1189.
24. Yamagishi S, Nakamura K, Ueda S, Kato S, Imaizumi T: Pigment epithelium-
derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via
suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF.
Cell Tissue Res 2005, 320:437–445.
25. Yamagishi S, Inagaki Y, Kikuchi S: Nifedipine inhibits tumor necrosis factor-
alpha-induced monocyte chemoattractant protein-1 overexpression by
blocking NADPH oxidase-mediated reactive oxygen species generation.
Drugs Exp Clin Res 2003, 29:147–152.
26. Inagaki Y, Yamagishi S, Okamoto T, Takeuchi M, Amano S: Pigment
epithelium-derived factor prevents advanced glycation end products-
induced monocyte chemoattractant protein-1 production in microvascular
endothelial cells by suppressing intracellular reactive oxygen species
generation. Diabetologia 2003, 46:284–287.
27. Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Okuda S,
Imaizumi T: Olmesartan blocks inflammatory reactions in endothelial
cells evoked by advanced glycation end products by suppressing
generation of reactive oxygen species. Ophthalmic Res 2008, 40:10–15.
28. Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S: Advanced glycation
end products evoke endothelial cell damage by stimulating soluble dipeptidyl
peptidase-4 production and its interaction with mannose 6-phosphate/insulin-
like growth factor II receptor. Cardiovasc Diabetol 2013, 12:125.
29. Yamagishi S, Matsui T, Nakamura K, Takeuchi M, Inoue H: Telmisartan inhibits
advanced glycation end products (AGEs)-elicited endothelial cell injury by
suppressing AGE receptor (RAGE) expression via peroxisome proliferator-
activated receptor-gammaactivation. Protein Pept Lett 2008, 15:850–853.
30. Kawanami D, Matoba K, Kanazawa Y, Ishizawa S, Yokota T, Utsunomiya K:
Thrombin induces MCP-1 expression through Rho-kinase and subsequent
p38MAPK/NF-κB signaling pathway activation in vascular endothelial cells.
Biochem Biophys Res Commun 2011, 411:798–803.
31. Xue J, Thippegowda PB, Hu G, Bachmaier K, Christman JW, Malik AB,
Tiruppathi C: NF-kappaB regulates thrombin-induced ICAM-1 gene
expression in cooperation with NFAT by binding to the intronic
NF-kappaB site in the ICAM-1 gene. Physiol Genomics 2009, 38:42–53.
32. Miho N, Ishida T, Kuwaba N, Ishida M, Shimote-Abe K, Tabuchi K, Oshima T,
Yoshizumi M, Chayama K: Role of the JNK pathway in thrombin-induced
ICAM-1 expression in endothelial cells. Cardiovasc Res 2005, 68:289–298.
33. Minhajuddin M, Fazal F, Bijli KM, Amin MR, Rahman A: Inhibition of
mammalian target of rapamycin potentiates thrombin-induced intercellular
adhesion molecule-1 expression by accelerating and stabilizing NF-kappa B
activation in endothelial cells. J Immunol 2005, 174:5823–5829.
34. Fukushima Y, Daida H, Morimoto T, Kasai T, Miyauchi K, Yamagishi S,
Takeuchi M, Hiro T, Kimura T, Nakagawa Y, Yamagishi M, Ozaki Y, Matsuzaki
M, JAPAN-ACS Investigators: Relationship between advanced glycation
end products and plaque progression in patients with acute coronary
syndrome: the JAPAN-ACS sub-study. Cardiovasc Diabetol 2013, 12:5.
35. Kato T, Yamashita T, Sekiguchi A, Tsuneda T, Sagara K, Takamura M, Kaneko S,
Aizawa T, Fu LT: AGEs-RAGE system mediates atrial structural remodeling in
the diabetic rat. J Cardiovasc Electrophysiol 2008, 19:415–420.
36. Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigorian-Shamagian L, Seoane-
Blanco A, Moure-González M, Varela-Román A, Álvarez E, González-Juanatey
JR: Evidence for a role of advanced glycation end products in atrial
fibrillation. Int J Cardiol 2012, 157:397–402.
37. Kubitza D, Becka M, Roth A, Mueck W: The influence of age and gender
on the pharmacokinetics and pharmacodynamics of rivaroxaban–an
oral, direct Factor Xa inhibitor. J Clin Pharmacol 2013, 53:249–255.
38. Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y: Immunological
evidence that non-carboxymethyllysine advanced glycation
end-products are produced from short chain sugars and dicarbonyl
compounds in vivo. Mol Med 2000, 6:114–125.
doi:10.1186/1475-2840-13-60
Cite this article as: Ishibashi et al.: Advanced glycation end products
potentiate citrated plasma-evoked oxidative and inflammatory reactions in
endothelial cells by up-regulating protease-activated receptor-1 expression.
Cardiovascular Diabetology 2014 13:60.
